Clerio Vision takes a step past LASIK (podcast)

Clerio Visio CEO, Mikael Totterman

Clerio Visio CEO, Mikael Totterman

Clerio Vision is developing a non-invasive, tissue-sparing laser technology that corrects vision by modifying the reactive index of the cornea. It’s the third med-tech spinout from the University of Rochester for CEO Mikael Totterman and is starting to get some press, including this BioTuesdays piece. I’m on the company’s board of directors.

I caught up with Mikael recently to discuss the company’s progress.

  • (0:20) Clerio is developing a laser technology for refractive eye surgery. We already have LASIK. Do we need another approach?
  • (2:44) So LASIK has downsides, but you also use lasers. What’s the difference?
  • (3:35) How do you test something like this? What testing has been done?
  • (4:51) If the technology is so promising, why did Bausch & Lomb stop development?
  • (6:30) What steps have you taken with the company since its founding?
  • (7:55) When can we expect to see a product on the market?
  • (8:56) This is at least the third company you’ve spun out of U of R. What is the biggest lesson that you learned and how are you applying these insights to Clerio?
  • (11:00) What sort of development costs are required for commercialization? How are you funded?
  • (12:08) What else should I know?
  • (13:25) When you make modifications to intraocular lenses for cataracts, do you do it before or after implantation?

—

By healthcare business consultant David E. Williams, president of Health Business Group.

 

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s